Abstract
Abstractd-Serine, a rare enantiomer of serine, is a biomarker of kidney disease and function. The level of d-serine in the human body is precisely regulated through the urinary clearance of the kidney, and its clearance serves as a new measure of glomerular filtration rate with a lower bias than creatinine clearance. d-Serine also has a direct effect on the kidneys and mediates the cellular proliferation of tubular cells via mTOR signaling and induces kidney remodeling as a compensatory reaction to the loss of kidney mass. In living kidney donors, the removal of the kidney results in an increase in blood d-serine level, which in turn accelerates kidney remodeling and augments kidney clearance, thus reducing blood levels of d-serine. This feedback system strictly controls d-serine levels in the body. The function of d-serine as a biomarker and modulator of kidney function will be the basis of precision medicine for kidney diseases.
Funder
Japan Society for the Promotion of Science
Japan Agency for Medical Research and Development
Publisher
Springer Science and Business Media LLC
Subject
Physiology (medical),Nephrology,Physiology
Reference71 articles.
1. Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11(2):156–63.
2. International Society of Nephrology. The under-recognized epidemic: Worldwide, over 850 million people suffer from kidney diseases. (2018). https://www.theisn.org/news/item/3317-the-hidden-epidemic-worldwide-over-850-million-people-suffer-from-kidney-diseases. Accessed 1 Oct 2018.
3. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003;108(17):2154–69.
4. Baigent C, Herrington WG, Coresh J, Landray MJ, Levin A, Perkovic V, et al. Challenges in conducting clinical trials in nephrology: conclusions from a kidney disease-improving global outcomes (KDIGO) controversies conference. Kidney Int. 2017;92(2):297–305.
5. Kimura T, Hesaka A, Isaka Y. d-Amino acids and kidney diseases. Clin Exp Nephrol. 2020;24(5):404–10.